The new National Comprehensive Cancer Network (NCCN) Guidelines for non-small cell lung cancer (NSCLC) added lorlatinib as a ROS1 treatment option, after progression on crizotinib or ceritinib. This means most insurance should start covering lorlatinib for ROS1.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (Version 2.2019) (subscription required, but it’s free)
Subsequent Therapy for ROS1 Rearrangement-Positive Metastatic NSCLC (NSCL-24)
Lorlatinib (category 2A) added as a treatment option, after progression on crizotinib or ceritinib.